Glycopyrrolate Injection, USP 4 mg/20 mL (0.2 mg/mL) 20 mL Multiple Dose Vial, 10vial carton, Rx ...

FDA Recall #D-0399-2023 — Class II — February 7, 2023

Recall #D-0399-2023 Date: February 7, 2023 Classification: Class II Status: Terminated

Product Description

Glycopyrrolate Injection, USP 4 mg/20 mL (0.2 mg/mL) 20 mL Multiple Dose Vial, 10vial carton, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA 20mL vial NDC 16729-474-05 UPC 3 16729 47405 4;carton NDC 16729-474-03 UPC 3 16729 47403 0

Reason for Recall

CGMP Deviations: recalling drug products following an FDA inspection.

Recalling Firm

Accord Healthcare, Inc. — Durham, NC

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

322 vials

Distribution

United States including Puerto Rico and Canada

Code Information

Batches: R2200431, Exp. Date 7/31/2023, R2200439, Exp. Date 9/30/2023

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated